The growing prevalence of hyperuricemia with the increase in age is expected to be the major driving factor for the growth of the xanthine oxidase inhibitors market over the forecast period. Lifestyle ...
XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat ...
TipRanks on MSN
XORTX highlights new gout genetics research, reshapes board and clarifies financing as Vectus deal nears closing
The latest announcement is out from XORTX Therapeutics Inc ( ($TSE:XRTX) ). On December 31, 2025, XORTX Therapeutics highlighted newly published, ...
Micot (Suzhou) Technology Co. Ltd. has disclosed xanthine derivatives reported to be useful for the treatment of hypertension and asthma.
TipRanks on MSN
XORTX leans into genetic breakthroughs in gout as it reshapes board and advances oxypurinol
XORTX Therapeutics Inc ( ($TSE:XRTX) ) has shared an announcement. XORTX Therapeutics highlighted newly published, large-scale genetic research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback